Dysport reduces muscle contractions by blocking the transmission of nerve impulses
News
PMGroup Worldwide Ltd welcomes MAD World Summit
Acquisition expands PMGroup’s commitment to transforming workplace health and organisational resilience
Argenx receives review from FDA for VYVGART in seronegative gMG
Regulator accepts supplemental application supported by positive phase 3 data
Nuclera extends Series C funding to advance antibody engineering
Investment to accelerate development of full‑format antibody capabilities on eProtein Discovery system
Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
New manufacturing technologies aim to accelerate next-generation cell therapy development
Fabentech secures French approval for Ricimed antidote
Authorisation marks major step in European preparedness against ricin
Oxford Drug Design reports major in vivo milestone for novel cancer therapy
Data shows potential route to overcoming resistance in aggressive colorectal tumours
Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
Partnership will analyse m6A RNA modifications in patient samples to support development of STC‑15
Excellence adventure
The first Excellence in Healthcare Partnerships (EHP) Awards and Networking Evening is afoot
MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
New biologic option shown to reduce exacerbations and extend time to first flare
Bial launches new sublingual Parkinson’s treatment in UK
Sublingual apomorphine film offers rapid relief for OFF episodes
Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
First‑in‑class SK ion channel inhibitor enters next stage of clinical development
Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
Company aims to expand treatment options for relapsed or refractory multiple myeloma
HUTCHMED begins phase 3 stage of pancreatic cancer trial
Combination therapy moves into late‑stage testing after encouraging earlier results
Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
Company prepares regulatory filings after treatment shows significant reduction in disease flare risk
